Please login to the form below

Not currently logged in
Email:
Password:

Zolgensma

This page shows the latest Zolgensma news and features for those working in and with pharma, biotech and healthcare.

Roche scores FDA approval for SMA drug risdiplam, now named Evrysdi

Roche scores FDA approval for SMA drug risdiplam, now named Evrysdi

Drug poised to challenge rivals Spinraza and Zolgensma. Roche has won approval from the US Food and Drug Administration (FDA) for its spinal muscular atrophy (SMA) drug risdiplam under the brand ... Following Spinraza to approval was Novartis’ one-shot

Latest news

More from news
Approximately 18 fully matching, plus 32 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics